Genmab A/S (NASDAQ:GMAB - Free Report) - Research analysts at HC Wainwright lifted their Q2 2025 earnings estimates for shares of Genmab A/S in a research report issued on Wednesday, April 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.41 per share for the quarter, up from their previous estimate of $0.39. HC Wainwright has a "Buy" rating and a $37.00 price objective on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S's Q3 2025 earnings at $0.44 EPS, Q4 2025 earnings at $0.45 EPS, FY2025 earnings at $1.48 EPS and FY2026 earnings at $1.72 EPS.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.
Several other equities analysts have also recently weighed in on the stock. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. Truist Financial cut their price target on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Finally, Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $39.17.
View Our Latest Stock Report on GMAB
Genmab A/S Trading Up 4.4 %
GMAB stock traded up $0.80 during trading on Thursday, reaching $18.81. The stock had a trading volume of 1,524,787 shares, compared to its average volume of 1,018,227. The firm has a market cap of $12.45 billion, a PE ratio of 10.81, a PEG ratio of 2.65 and a beta of 1.07. The stock's 50 day moving average is $20.48 and its two-hundred day moving average is $21.31. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $30.41.
Hedge Funds Weigh In On Genmab A/S
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. grew its holdings in Genmab A/S by 94.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company's stock valued at $636,000 after purchasing an additional 12,654 shares during the last quarter. AIMZ Investment Advisors LLC bought a new position in shares of Genmab A/S during the fourth quarter valued at approximately $3,525,000. HighTower Advisors LLC purchased a new stake in shares of Genmab A/S in the third quarter worth approximately $273,000. FMR LLC lifted its stake in shares of Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after acquiring an additional 33,076 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Genmab A/S by 229.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company's stock valued at $1,033,000 after acquiring an additional 34,652 shares during the period. Hedge funds and other institutional investors own 7.07% of the company's stock.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
